In India, ischemic heart disease is the leading cause of death and premature death, and high blood pressure (BP) is the fourth leading risk factor of death and disability.
1 In a recent study in JAMA Internal Medicine, Geldsetzer et al 2 reported the first national prevalence rate of hypertension in India to be 25%, based on a systolic BP of 140 mm Hg or higher or a diastolic BP of 90 mm Hg or higher, as defined in the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure guidelines (JNC7). 3 In 2017,
the American College of Cardiology/American Heart Association (ACC/AHA) Task Force on Clinical Practice Guidelines reduced the systolic BP and diastolic BP threshold for stage 1 hypertension to 130/80 mm Hg and recommended the initiation of BP-lowering medication if the patient's 10-year risk for cardiovascular disease (CVD) is 10% or greater or if the patient has known clinical CVD, diabetes, or chronic kidney disease. 4 The objective of the present study was to estimate the difference in hypertension prevalence in India depending on whether the JNC7 or the ACC/AHA guidelines were applied.
Methods | This study was exempt from review by the institutional review board of the Harvard T.H. Chan School of Public Health and the institutional ethics committee of the Public Health Foundation of India, as the study was a secondary analysis of data available in the public domain. Data analysis was conducted from February 4, 2018 , to February 14, 2018 . We used data from the District-Level Household Survey-4 (DLHS4) and the Annual Health Survey (AHS) carried out between 2012 and 2014 in all of the 29 states, except Jammu, Kashmir, and Gujarat, and 5 of the 7 union territories in India. During the surveys, each household member 18 years or older, excluding pregnant women, underwent 2 BP measurements while seated; an electronic sphygmomanometer was used on the left arm, and the 2 readings were taken at least 3 minutes apart. Hypertension was determined using the mean of the 2 readings, according to JNC7 or ACC/AHA guidelines. Hypertension prevalence was weighted to the age structure of India's population in 2013. The difference in hypertension prevalence, overall and by demographic and socioeconomic subgroups, was estimated. The 10-year risk for CVD was calculated using the Framingham office-based CVD risk score among those aged 30 to 74 years with ACC/AHA stage 1 hypertension. The details of this analysis are published elsewhere. Table 1) . The new BP threshold showed the greatest increase in prevalence of hypertension in the youngest age group (aged 18 to 25 years) and resulted in slightly greater increases in prevalence among those living in rural compared with urban areas (146.4% vs 130.0%) and those in the poorest compared with the richest households (160.5% vs 119.3%) ( Table 2) .
Discussion | The lowered BP threshold in the new ACC/AHA guidelines resulted in a 140% relative increase in the hypertension prevalence in India. This increase was 3 times higher than the 43% relative increase reported in the United States.
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The prevalence reported in our analysis is likely an underestimate, given that the DLHS4 and the AHS did not collect information on antihypertensive medication use; thus, this study considered those individuals who achieved BP control with medication to not have hypertension.
Such an increase in the hypertension prevalence in India is likely to have significant implications for the Indian health system. Greater increases among younger patients and those from rural and poorest households may exacerbate the existing access-to-care issues in these high-risk subgroups. Hypertension treatment and control rates are already very low in India. 6 The current health system, beset with an irregular supply of drugs and high load of patients, is unlikely to have the capacity to absorb such a significant surge in new patients. In our view, adoption of the new ACC/AHA guidelines in India is 
Assessment of Clinical Trial Evidence for High-Risk Cardiovascular Devices Approved Under the Food and Drug Administration Priority Review Program
This study evaluates the randomized clinical trials conducted to provide evidence of the safety and effectiveness of cardiovascular devices approved by the Food and Drug Administration (FDA). The FDA approves high-risk devices through premarket approval if it determines the device provides reasonable assurance of safety and effectiveness. The dual goals of this approval process are to ensure patient safety and facilitate access to beneficial technologies. For the past several decades, priority review mandated by legislation has intended to hasten FDA approval, whereby an application receives precedence in review and additional review resources, if needed. For all studies, we analyzed these design features: number of patients enrolled, randomization, blinding, use and type (active or retrospective) of controls, and post hoc analysis. For all primary end points, we analyzed these characteristics: composite, surrogate, type of analysis (noninferiority, superiority, or objective performance criteria), and achievement of end point. If a device went to an FDA expert device panel, we analyzed the panel's recommendations. We tabulated the postapproval study requirements and the existence of either a Class I ("a reasonable probability that the use … will cause serious adverse health consequences or death") or a Class II ("may cause temporary or medically reversible adverse health consequences or … the probability of serious adverse health consequences is remote") recall. Eighteen pivotal studies were conducted for the 14 cardiovascular devices, and a mean (SD) of 1.3 (0.5) pivotal studies supported each device. None of the 18 studies was double-blind, and 13 studies (72%) used surrogate end points ( Table 1) . The studies enrolled a mean (SD) of 499 (542) patients. Nine studies used a noninferiority hypothesis for at least 1 primary end point. Three device approvals included post hoc analyses, and 2 of these devices did not meet any prespecified primary end points. 
